BONTRIL PDM SUMMARY
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines.
Bontril® PDM (phendimetrazine tartrate) is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below.
Media Articles Related to Bontril PDM (Phendimetrazine)
Childhood Obesity: Has the Tide Really Turned?
Source: Medscape Pediatrics Headlines [2014.03.06]
Recent headlines blared that obesity rates in toddlers had plummeted 40%. Do the data really support that conclusion?
Discovery could lead to further advances against diseases tied to obesity and type II diabetes
Source: Diabetes News From Medical News Today [2014.03.06]
Researchers at NYU Langone Medical Center have found that blocking the action of a key signaling molecule in the immune system known as Netrin-1 stalls chronic inflammation and insulin resistance tied to obesity and often derived from fatty diets.
Obesity Rates Triple in Canada
Source: MedicineNet Obesity (Weight Loss) Specialty [2014.03.06]
Title: Obesity Rates Triple in Canada
Category: Health News
Created: 3/5/2014 12:35:00 PM
Last Editorial Review: 3/6/2014 12:00:00 AM
Children with ADHD have higher risk of teenage obesity and physical inactivity
Source: ADHD News From Medical News Today [2014.03.05]
Children with attention deficit hyperactivity disorder (ADHD) are more likely to become obese and sedentary teenagers, according to new research.Previous studies have suggested a link between ADHD and obesity, but whether one leads to the other is unclear. One way to better understand the link is to follow children through to adolescence.
Obesity rates in Canada have tripled in less than 3 decades
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2014.03.05]
Obesity rates in Canada tripled between 1985 and 2011, from 6% to 18%, with significant increases in the very obese categories; it is projected that approximately 21% of Canadian adults will be obese by 2019, according to an article published in CMAJ Open.
Published Studies Related to Bontril PDM (Phendimetrazine)
Rare case of rhabdomyolysis with therapeutic doses of phendimetrazine tartrate. [2006.03]
Phendimetrazine tartrate is a newer drug that acts as a central stimulant and indirectly acting sympathomimetic with a host of uses similar to the class amphetamines... Additional awareness is needed to educate their patients about the side effects associated with these drugs and to strongly discourage their unsupervised use.
Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine. [1998.10]
A 47-year-old mildly obese female began a weight reduction program that included anorectic therapy with phentermine and phendimetrazine. A normal urinalysis and serum creatinine were documented at the start of therapy... This case represents the first report of acute interstitial nephritis associated with phentermine or phendimetrazine.
A simple gas chromatographic identification and determination of 11 CNS stimulants in biological samples. Application on a fatality involving phendimetrazine. [1989.02]
A method is presented for the simultaneous identification and quantification of several CNS stimulants, including amphetamine in plasma and urine by GC/FID using mephentermine as an internal standard.
Fatality from illicit phendimetrazine use. 
Phendimetrazine is an anorectic agent which recently has been detected in three medical examiner's cases. In one instance death was attributed to this drug... In the one instance where death was attributed to this substance, the blood concentration was 300 ng/ml.